Biocartis Spins Out Life Sciences Multiplex Platform Evalution into Mycartis
News Sep 06, 2014
Biocartis has announced that it has combined its Swiss Evalution business unit with Belgian-based Pronota NV to jointly form MyCartis. MyCartis also completed an EUR 15 million equity round.
Biocartis’ Evalution platform, previously known as DMAT, is designed for rapid and cost-effective detection of a broad range of protein and nucleic acid biomarkers, making the system valuable for many clinical and pharmaceutical applications. Pronota has discovered and validated biomarker panels for a range of diseases.
As such this content is an ideal match for Biocartis’ Evalution platform. MyCartis will continue the development of biomarker panels from the current Pronota laboratories (Technology Park, Ghent), to complement the current activities in Switzerland (Parc Scientifique - EPFL, Ecublens).
In order to execute and roll out MyCartis’ future ambitions, MyCartis has completed a financing round of EUR 15 million. The capital is subscribed by RMM (Rudi Mariën), Valiance and Biover II (Annie Vereecken). Paul Ladestein is appointed as MyCartis’ Chief Executive Officer.
Paul joined Biocartis in 2013 as Evalution business unit manager. Being responsible for the establishment and expansion of Luminex EMEIA during the last 11 years, Paul has gained a lot of relevant expertise in serving the life sciences research and diagnostics space with multiplex technologies.
“We believe MyCartis is now all set for the launch of Evalution as a molecular biomarker multiplexing technology this fall. Furthermore, by combining the assets of Evalution with Pronota’s biomarker discovery expertise, MyCartis will be able to further expand its offering in the future,” said Rudi Pauwels, CEO & Executive Chairman of Biocartis.
“This business combination with Biocartis’ Evalution platform offers the potential to capture the full value of Pronota’s biomarker assets. With the strong financial backing, MyCartis is well positioned for future growth and success,” said Johan Cardoen, Chairman of Pronota.
Paul Ladestein, CEO of MyCartis, added: “We are convinced that Evaluation is a very powerful multiplexing detection system bringing unique capabilities that allow laboratories to perform both protein and nucleic-acid biomarker analysis on the same sample, within the same assay plate.”
Detecting Heart Damage Long Before Parkinson's Symptoms AppearNews
Mapping inflammation in the heart before diagnosis of Parkinson's disease: a new tool for tracking treatment efficacyREAD MORE
3D Super-Resolution Nanoscopes Used To Identify Amyloid PlaquesNews
A new development in 3D super-resolution imaging gives insight on Alzheimer's diseaseREAD MORE